Prisma Health Midlands to Pay $1 Million to Resolve Alleged Controlled Substance Act Violations - DEA.gov
Prisma Health Midlands agrees to pay $1 million to resolve alleged Controlled Substance Act violations, highlighting DEA enforcement risks for healthcare entities handling controlled substances.
Aforeworn detected this change in the Pharmacy & Controlled Substances space on August 1, 2026 and published this briefing so affected operators are forewarned rather than caught off guard. It is rated Medium urgency. Healthcare organizations, pharmacies, and practitioners that handle controlled substances, especially those in the Midlands region or affiliated with Prisma Health. should confirm how it applies to their specific situation before acting. There is a time constraint attached: Not specified in the provided text.. Acting after that point can mean penalties, a lapsed licence, or lost eligibility — exactly the kind of surprise Aforeworn exists to prevent. Aforeworn monitors Pharmacy & Controlled Substances continuously and turns every detected change into a plain-English briefing like this one, so you always know first. Forewarned is forearmed.
What changed
A specific enforcement action against Prisma Health Midlands, resulting in a $1 million settlement for alleged Controlled Substance Act violations.
Who it affects
Healthcare organizations, pharmacies, and practitioners that handle controlled substances, especially those in the Midlands region or affiliated with Prisma Health.
What you must do
Review internal controlled substance handling, prescribing, and dispensing practices to ensure compliance with the Controlled Substance Act and DEA regulations.
Deadline
Not specified in the provided text.
Never miss a change like this again
Aforeworn watches Pharmacy & Controlled Substances around the clock and alerts you the moment a rule moves — with a plain-English brief on what to do.
Start your free trialRelated changes in Pharmacy & Controlled Substances
- US-CONGRESS HR1266: Combating Illicit Xylazine Act
- Louisiana v. FDA: Access to Mifepristone Back at the Supreme Court - kff.org
- Assessing Adhesion With Transdermal and Topical Delivery Systems for ANDAs; Guidance for Industry; Availability
- Amendment to 3,4-MDP-2-P Methyl Glycidic Acid, a List I Chemical
- Utah opens applications for another medical cannabis license - mjbizdaily.com